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Academy of Sciences, 810008 Xining, China.
Abstract: Human serum albumin (HSA) is the major protein in blood plasma and is responsible for circulatory transport
of a range of small molecules including fatty acids, metal ions and drugs. We previously identified the major plasma Zn2+
transport site on HSA and revealed that fatty-acid binding (at a distinct site called the FA2 site) and Zn2+ binding are
interdependent via an allosteric mechanism. Since binding affinities of long-chain fatty acids exceed those of plasma Zn2+,
this means that under certain circumstances the binding of fatty acid molecules to HSA is likely to diminish HSA Zn2+-
binding, and hence affects the control of circulatory and cellular Zn2+ dynamics. This relationship between circulatory
fatty acid and Zn2+ dynamics is likely to have important physiological and pathological implications, especially since it
has been recognised that Zn2+ acts as a signalling agent in many cell types. Fatty acid levels in the blood are dynamic, but
most importantly, chronic elevation of plasma fatty acid levels is associated with some metabolic disorders and disease
states – including myocardial infarction and other cardiovascular diseases. In this article, we briefly review the metal-
binding properties of albumin and highlight the importance of their interplay with fatty acid binding. We also consider the
impact of this dynamic link upon levels and speciation of plasma Zn2+, its effect upon cellular Zn2+ homeostasis and its
relevance to cardiovascular and circulatory processes in health and disease.
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1. INTRODUCTION
Zinc is recognised as an important micronutrient [1,2]. At
least 10% of all human proteins require a structural or
catalytic zinc cofactor [3]. In addition, zinc acts as an
intracellular and extracellular signalling agent [4]. In
consequence, zinc is involved in virtually every conceivable
biological process, and thus the organismal zinc status
affects for example, growth and development, the immune
system, mental health, as well as cardiac health. It must also
be noted that zinc, as the free Zn2+ aquo-ion, is toxic to cells
at very low concentrations [5]. Given its ubiquity,
essentiality and potential cell toxicity, cellular zinc
homeostasis [6,7] is usually well-controlled, involving no
less than 24 membrane-bound transporters of the ZIP and
ZnT families [8], and at least 13 expressed metallothioneins
[9]. Alterations in zinc homeostasis are known to occur with
increasing age [10], and in some of the most prevalent
diseases [11], including neurodegenerative diseases, cancer,
diabetes and cardiovascular disease (CVD) [12]. In many
cases, it has remained obscure whether these alterations are
cause or consequence, or both, of the respective disease
state, and occasionally, it is even unclear whether the
observed alterations are harmful or beneficial.
Mammalian zinc homeostasis on the organismal level
also involves the circulatory system [13]. Although zinc
plasma levels (reference values are around 16.6±6.2 µM
[14]) are affected by a range of conditions ([15], also see
section 4), they are not decreased by mild zinc deficiency
[16]. This suggests that plasma zinc levels are also subject to
tight control – and it is important to understand how this
control works. Apart from the crucial importance of ZIP and
ZnT transporters, it is conceivable that this is also influenced
by Zn2+ binding to components of plasma – and chief
amongst these is serum albumin [17]. Our studies have
revealed that albumin directly links plasma zinc and free
fatty acid (FFA) dynamics through allosteric binding. In the
present review, we will explore how this allosteric link may
impact on cardiovascular health and disease. Our findings
also have direct implications for the diagnostics of
myocardial ischemia through the biomarker "ischemia-
modified albumin" (IMA), and since there is much confusion
in the current literature regarding this, we will begin with a
summary of the current state of the art on metal ion-albumin
interactions.
2. The multi-metal binding site on serum albumin and its
allosteric regulation by fatty acids
Albumin is not only the most abundant plasma protein
(ca. 640 µM; 40 g/L), but under normal conditions also binds
the vast majority of exchangeable plasma Zn2+ [18]. Metal
binding to mammalian serum albumins has been studied for
several decades [19], and it is now clear that most albumins
harbour at least four distinct metal-binding sites [20,21]: best
known is perhaps the N-terminal "ATCUN" (Amino-
Terminal Copper and Nickel) binding motif [22], followed
by two sites detectable by 113Cd NMR spectroscopy, called
site A and B [23-25], and lastly the free thiol of Cys34 [26].
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The latter is only relevant for very thiophilic xenobiotic
metal ions such as Au+ [27], Pt2+ [28] and Hg2+ [29], whereas
the former three sites are capable of binding a range of 3d
metal ions including Cu2+, Ni2+, Co2+, Mn2+ and Zn2+.
These divalent metal ions and Cd2+ display different
preferences for the ATCUN site, site A and site B. Taking
advantage of the Jahn-Teller effect, the d8 and d9 ions Ni2+
and Cu2+ show a distinct preference for the square-planar
geometry provided by the ATCUN motif [22,30,31]. This
binding mode involves the unprotonated terminal amino
group and the imidazole side-chain of His3, and requires the
deprotonation of two backbone amides. Both Cu2+ and Ni2+
can elicit this deprotonation at physiological pH, but Zn2+
and Co2+ require a much higher pH to effect significant
binding to model peptides [32]. Instead, the closed-shell Zn2+
ion prefers the distorted site A [23,24,33] (dissociation
constant KD = 0.3-40 µM [34-37]), and the highest affinity
site for Co2+ (high-spin d7) has been determined as site B (KD
= 11 µM [38]), followed by site A (90 µM) and, lastly,
ATCUN (110 µM) [38]. Cu2+ binds with picomolar affinity
to the ATCUN site [31], and with a KD = 10 nM to site A
[39]. The respective values for Ni2+ are 150 nM [40] and
12.5 µM [41].
Site A has also been termed the multi-metal binding site
(MBS) [39,41]: whilst it is a primary site for Zn2+ and Cd2+,
it is a secondary site for Cu2+, Ni2+ and also Co2+. This means
that whenever more than one equivalent of the latter ions are
added to pure, ligand- and metal-free albumin, this site will
become significantly occupied by the respective metal ion. It
is also important to note that in human and bovine serum
albumin (HSA and BSA), Cu2+ still forms stronger
interactions with this site than either Cd2+, Ni2+ Co2+, or Zn2+
[40]. This is in keeping with expectations based on the
Irving-Williams series, which describes the order of
affinities of divalent high-spin complexes [42].
The location [33] and structure [43] of the major zinc site
(and hence the secondary site for Co2+, Ni2+, and Cu2+) have
been determined using a range of spectroscopic techniques,
although no X-ray crystallographic studies on any Zn-
albumin complexes are as yet available. The most striking
peculiarity of this site is its location at the domain interface
between domain I and domain II of HSA (Figures 1a and b).
It is formed by two residues from each domain: His67 and
Asn99 from domain I and His247 and Asp249 from domain
II. These four residues are conserved in albumins from
mammals. A copious amount of X-ray crystallographic
studies have been carried out on HSA [44-53], with
structural information on other serum albumins having
become available recently [54,55]. Inspection of these
structures reveals that the MBS is consistently only present
in fatty acid-free preparations [33] (Figure 1c). Fatty acids
are the primary ligands for albumin, and albumin is the
primary plasma transporter for long-chain unesterified (or
"free") fatty acids (FFA), which are the primary source of
energy for the myocardium. The origin of disruption of the
MBS is traceable to the FFA binding site FA2 [46], which
significantly also requires interacting residues from both
domains I and II (Figure 1d). Although there is no overlap
between the zinc- and fatty-acid binding residues, the
domain-domain movement that is required to form the FFA
binding pocket essentially leads to the destruction of the
preformed zinc-binding site [33]. This observation raised the
question whether zinc binding inhibited fatty acid binding to
this site, or vice versa. Isothermal titration calorimetry (ITC)
studies involving the ternary system BSA, Zn2+ and
myristate clearly demonstrated that the C14 fatty acid
inhibited zinc binding to albumin (Figure 2d) [37]. Recent
studies confirmed that fatty acids inhibit zinc binding to the
MBS also in HSA (Figure 2a) [56].
This allosteric switch is expected to have multiple
physiological consequences, further described in sections 3
and 4. Under normal conditions, between 0.1 and 2 FFA
molecules are carried per albumin molecule [19,57], but
there a number of conditions, including fasting, extreme
exercise [58], obesity, metabolic syndrome, diabetes
mellitus, and cardiovascular disease [59] including
atherosclerosis and myocardial infarction [60], under which
up to four [19], or even more [61], FFA molecules can
become bound. Importantly, many of these conditions are
also associated with considerable shifts in plasma zinc
levels, and these observations, together with our structural
and thermodynamic studies, have led us to hypothesise that
these correlations are mediated by HSA [15] - the main
transporter for both zinc and FFAs in plasma. However, it
should be stressed that FFA effects on zinc speciation and
distribution are not expected to be restricted to such drastic
conditions - we observed marked differences in zinc affinity
and binding capacity even at just 1 molar equivalent of
myristate for both BSA and HSA (Figures 2a and b) [37,56].
This is consistent with observations by the group of
Hamilton that indicated that FA2 is one of the highest-
affinity FFA binding sites on HSA [62,63].
One further momentous implication of this allosteric
switch is based on the fact that MBS is, as mentioned earlier,
also a secondary binding site for other M2+ metal ions. This
simply means that the Co2+ (and Cu2+ and Ni2+) binding
capacity and affinity of albumin will also be affected by fatty
acid levels, and for Co2+, this has indeed been demonstrated
(Figure 2e). Myocardial ischemia is one of the many
conditions in which FFA levels are significantly elevated.
Hence, the FFA-mediated allosteric switch also effortlessly
explains the reduction in metal binding in diagnostic tests
related to the Albumin-Cobalt-Binding (ACB) test [64,65],
as well as the identity of the elusive biomarker "Ischemia-
Modified Albumin" (IMA): IMA is simply albumin with a
higher ratio of FFA bound. The case for this assertion, as
well as ensuing implications, will be laid out in section 5.
3. FFA-mediated alterations in plasma zinc speciation:
Implications for neutralisation of heparins
Zinc is an important regulator of coagulation following
its release from activated platelets [66]. The resultant local
increases in Zn2+ concentration are sensed by a range of
haemostatic proteins to stimulate a pro-coagulatory response
[67]; this represents an essential transition phase that
promotes the propagation of coagulation. Plasma proteins
that bind Zn2+ under these conditions include histidine-rich
glycoprotein (HRG), a key effector molecule upon which
Zn2+ acts to regulate coagulation [68,69]. HRG is a 75 kDa
glycoprotein present at a concentration of 1.3-2.0 μM in 
adult blood [69,70].
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Figure 1. Structural basis of allosteric binding of zinc and fatty acids to serum albumin. (a) Location of inter-domain zinc
site A (MBS) (b) [43] and fatty-acid binding site FA2 (d) [46]. The three domains of albumin are shown in grey (domains I and
III) and black (domain II). (b) shows a close-up of the distorted 5+1 metal binding site; the backbone carbonyl oxygen of
His247 also forms a long bond to the Zn2+ ion. In (d), the four zinc-binding residues are shown with thin lines, and some
residues forming the two halves of the FA2 binding pocket are shown as sticks, with the resolved part of a myristate molecule
shown in space-filling mode. (c) MBS residues in a selection of X-ray structures with and without (pdb 4G03, 2BXH, 4F5V
(rabbit SA), 3V09 (rabbit SA), 3JRY, 1E78, 1AO6, 4K71 (HSA in complex with the Fc receptor) [45,50,51,53,54,55]) bound
fatty acids (decanoate (1E7E), dodecanoate (1E7F), myristate (3SQJ, 1E7G), palmitate (1E7H), stearate (1E7I), oleate (1GNI),
arachidonate (1GNJ) [47,48]). The overlay was generated by aligning the backbone atoms of residues His247, Gly248, and
Asp249 in Swiss pdb viewer v. 3.7.
We recently demonstrated that HRG possesses ten Zn2+
sites (with an average apparent Kd of ~6 μM) and that Zn2+-
binding enhances the ability of HRG to bind and neutralize
long-chain heparins [56]. Under normal conditions heparin
binds to and stabilizes the anticoagulatory antithrombin
III/thrombin complex. During clotting, thrombin cleaves
fibrinogen into insoluble strands (fibrin) that are cross-linked
by factor XIII to form a blood clot [71]. Zn2+-dependent
neutralization of heparin by HRG provides increased
competition for heparin binding to this complex, which may
result in release of thrombin and an increase in its activity,
which will ultimately promote clotting.
Speciation modelling experiments based upon affinity
and stoichiometry data for Zn2+-binding to HRG and to
albumin (in the absence and presence of various
concentrations of myristate) suggested that the FFA-
mediated reduction in availability of the MBS increases the
proportion of plasma Zn2+ bound to HRG (Figure 2c), such
that its ability to neutralize heparins will be increased [56].
However, it is important to point out that this simple model
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only considered serum albumin and HRG and did not take
into account other circulatory proteins that could bind
displaced Zn2+. These include other components of the
blood-clotting cascade [67], as well as numerous
components of the immune system [72]. It is also important
to point out that HRG can also associate with molecules
other than heparin (such as tropomyosin, factor XIIa and
soluble IgG) in a Zn2+-dependent manner [69,73], thus the
actions of increased Zn2+-binding to HRG are likely to be
complex.
Interestingly, a recent study by Fredenburgh et al. has
revealed that fibrinogen, like HRG, also binds heparin with
high affinity in a Zn2+-dependent manner [74]. Fibrinogen is
a glycoprotein present in plasma at a concentration of around
6-12 μM [71,75]. The study by Fredenburgh et al. revealed
that Zn2+ binds fibrinogen with a Kd in the low micromolar
range; values of 9.4 μM and 4.5 μM were measured using 
surface plasmon resonance and a fluorescence-based assay,
respectively. Furthermore, they found that Zn2+ promotes a
4-fold increase in heparin binding to fibrinogen. This study
highlights the fact that Zn2+ can potentially influence heparin
neutralization by fibrinogen as well as by HRG. Also a
further reduction of heparin activity will occur when
fibrinogen is clotted because heparin promotes thrombin
binding to fibrin and induces the formation of a complex that
limits inhibition by antithrombin [76,77]. Zinc also
stimulates platelet aggregation by promoting fibrinogen
binding to αIIbβ3, its cognate receptor on the platelet surface
[66,78].
The observations above are particularly interesting as
disorders characterized by chronically elevated levels of
plasma fatty acids are associated with an increased risk of
thrombosis [79,80]. These include obesity [81,82], diabetes
[83], fatty liver disease [84], and cancer [85]. For example,
thromboembolism (caused by obstructive blood clots) is the
second leading cause of death associated with malignancy
[79]. Collectively, these observations suggest that under
conditions where FFA levels are elevated, Zn2+ displaced
from serum albumin could bind HRG or fibrinogen to
enhance their respective interactions with heparins and
induce a pro-coagulatory effect [86], as summarized in
Figure 3. In older adults, this may be further compounded as
plasma albumin levels are known to decrease with age [87].
An age-related decrease in plasma albumin also correlates
with an observable increase in the ratio of FFAs per albumin
molecule [88]. It is important to point out that the degree to
which each of the respective proteins, HRG and fibrinogen,
contribute to Zn2+-dependent neutralization of heparins
remains to be determined. However, evidence for a direct
link between defective plasma Zn2+-handling, mediated by
FFA-displacement of Zn2+ from albumin, and thrombotic
risk is compelling.
Figure 2. Impact of fatty acids on binding site availability on albumin for Zn2+ and Co2+ and consequences thereof. (a)
and (d) Myristate-induced reduction in availability of site A (MBS) for HSA and BSA, as determined by isothermal titration
calorimetry [37,56]. (b) and (c) Plasma speciation modelling suggested that the reduction in binding site availability may result
in an increase of free Zn2+ and zinc bound to HRG [56]. (e) ITC experiments revealed a similar reduction of overall binding site
availability for Co2+ [149]. One out of three possible binding sites is lost in the presence of 5 mol. equiv. of myristate. ND
indicates that no data is available. (f) Myristate binding to BSA leads to increased Co-DTT complex formation in the ACB
assay [149]. The line is drawn to guide the eye and does not represent a fit.
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Figure 3. Diagram illustrating the mechanisms by which
Zn2+ may influence coagulation through stimulation of
HRG- and fibrinogen-dependent pathways.
4. Cellular effects of altered plasma zinc speciation and
cardiovascular disease
A number of studies have examined the association of
zinc with coronary diseases, cardiomyopathies and
arrhythmias, and links between etiopathogenesis of CVD
have been suggested [89-91]. Aberrant Zn2+-homeostasis is
associated with cardiomyopathy including chronic heart
failure and myocardial damage [11,89], as well as primary
arterial hypertension [92,93]. Many intracellular enzymes
and other proteins involved in regulating cardiac function are
Zn2+-dependent [89]; furthermore, zinc homeostasis and
intracellular redox balance are intimately linked [6,94].
Therefore, the impact of zinc on cardiovascular health is
most probably multifactorial; some potential mechanisms
and pathways are discussed in this section.
4.1. Potential impact of albumin on cellular zinc
homeostasis
Intracellular zinc concentrations are known to be
regulated largely by zinc transporters, zinc binding proteins
including metallothioneins, and zinc sensors [6,7], but the
extracellular space also participates in zinc dynamics.
Indeed, various studies have suggested that serum albumin
helps to regulate the uptake of Zn2+ by a range of cell types.
For example, serum albumin facilitates the uptake of Zn2+
into endothelial cells [95] and erythrocytes [96]. Also
receptor-mediated vesicular co-transport of Zn2+ with
albumin across the endothelium has been demonstrated in
vitro [97]. Despite this, any direct role for albumin in
mediating delivery of Zn2+ to cells via endocytosis is likely
to be relatively minor as only ~2% of circulating albumin
molecules carry Zn2+ at any one time. The primary function
of albumin in mediating Zn2+ uptake is through maintenance
of the plasma exchangeable zinc pool. Ultimately, Zn2+ will
cross cell membranes predominantly through ZIP (transport
from plasma into cells) and ZnT (transport into plasma)
transporters. Crucially, the activity of these transporters
depends on availability of free Zn2+ – and this in turn is
regulated by the assortment of molecules that can reversibly
bind Zn2+ in plasma. If the zinc-binding capacity of plasma
drops, this may lead to an increase in free Zn2+ (Figure 2b),
which should, in the first instance, result in increased cellular
uptake. This may manifest in decreased levels of plasma
zinc. Intriguingly, the same conditions that are associated
with high FFA levels, including congestive heart failure,
myocardial ischemia and infarction, are also known to result
in decreased plasma zinc [98,99] – more precisely,
exchangeable, albumin-bound zinc [100,101]. This is
consistent with the idea that in these conditions, the
increased FFA levels lead to lower zinc-binding capacity by
albumin, and an increase in free Zn2+ available for cellular
uptake. We hypothesise that conditions that lead to elevated
plasma FFA might cause significant changes to cellular zinc
homeostasis, at the very least in cells in direct contact with
plasma, including erythrocytes, platelets, macrophages, B-
and T-cells, endothelial cells, but potentially also vascular
smooth muscle cells (VSMC) and cardiomyocytes. Based on
the facts that both a lack of zinc [102] as well as excessive
extracellular free Zn2+ [5] has deleterious effects on cells in
general, any large perturbation of plasma zinc homeostasis
may be expected to have direct or indirect detrimental
consequences for cells. Some possible effects are described
below.
4.2. Effects of zinc on intracellular calcium signalling in
cardiomyocytes
Ca2+ is crucially involved in the function of
cardiomyocytes and VSMCs [103], with intracellular Ca2+
release from the sarcoplasmatic reticulum through ryanodine
receptors triggering the contraction of these muscle cells
[104]. CVD has been linked to dysregulated intracellular
Ca2+ release, reduced cardiac contractility and prolonged
rises of systolic Ca2+ [105]. There is cross-talk between the
fluxes of Ca2+ and Zn2+ [106]; hence, it is thought that zinc
dyshomeostasis will impact on Ca2+ trafficking in
cardiomyocytes (as recently reviewed in [107]). Various
studies suggest that defective Zn2+ handling contributes to
cardiomyopathies including altered contractility and heart
failure [89,108-110]. Indeed, it has been hypothesised that
increased cytosolic Zn2+ can influence cardiac excitation-
contraction coupling through regulation of the ryanodine
receptor in cardiomyocytes [111,112]. The combined effects
of Zn2+ and Ca2+ dyshomeostasis are also thought to generate
oxidative stress, lead to cardiac myocyte necrosis and
replacement fibrosis [113].
4.3. Blood pressure effects of zinc
Changes of both intracellular and extracellular zinc
contents have been documented for primary arterial
hypertension [92,93]. Serum zinc levels are decreased in
arterial hypertension, as are those in lymphocytes and bone,
whereas zinc levels in erythrocytes, heart, liver, kidney and
various glands are increased; overall, the organism becomes
zinc-deficient. It has remained unclear whether this systemic
zinc dyshomeostasis is cause or consequence of arterial
hypertension. Lower plasma zinc levels are suggested to
impact on Ca2+ fluxes, and the activities of angiotensin-
converting enzyme (ACE), endothelin-converting enzyme,
and neutral endopeptidase. Increased erythrocyte zinc is
associated with increased carbonic anhydrase activity, which
may result in increased blood pH. Angiotensins are
vasoconstrictors; thus a decrease in ACE activity leads to
increased levels of angiotensins and hence increased blood
pressure. Also endothelial NO-synthase (eNOS) is involved
in the generation of the vasodilator NO, hence important for
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the regulation of blood pressure. eNOS contains a structural
zinc site that is essential for enzyme function; its disruption
by reactive oxygen and nitrogen species has been
demonstrated [114]. Thus, zinc dyshomeostasis may either
directly or indirectly affect its activity, with a lack of zinc
expected to lead to decreased NO levels and hence increased
blood pressure.
4.4. Zinc dyshomeostasis in atherosclerosis
The major underlying mechanism in the development of
CVD is the formation of atherosclerotic plaques in the wall
of blood vessel which eventually leads to stroke, heart attack
and lower limb disease [115,116]. There is much evidence
that zinc deficiency is pro-atherogenic [117]. A number of
pathways have been invoked to explain this correlation, as
summarized in Figure 4. For example, inflammation is
known to play a major role in the development of
atherosclerosis [118]. Zinc has been shown to impact on
several of the molecules that have been implicated in this
etiology. For instance, the zinc-dependent [119] transcription
factor NF-кB, a key element in regulation of inflammatory 
responses [120] may in many cells be regulated by Zn2+
status [121]. NF-кB regulates amongst others the expression 
of vascular cell adhesion molecule (VCAM)-1, ICAM-1, E-
selectin, cytokines of the interleukin family, plasminogen
activator inhibitor (PAI)-1, and inducible nitric oxide
synthase (iNOS). Cytokine transcription is also directly
regulated by zinc [122], and several cytokines (IL-β, IL8 and 
TNF-α) themselves induce expression of E-selectin, ICAM 
and VCAM. This results in trapping of monocytes, platelets,
neutrophils and erythrocytes, which subsequently block
blood vessels.
Figure 4. Schematic illustration showing how elevated
plasma FFA levels may influence cell metabolism such as
to impact upon pro-atherosclerotic pathways.
Zinc also impacts on various other signalling networks,
including those involving protein kinase C (PKC), which
plays a central role in many signalling pathways in
endothelial and vascular smooth muscle cells [123].
Thrombin, angiotensin and endothelin all trigger the
activation of PKC, via signalling cascades involving G-
protein-coupled receptors and phospholipase C. The latter
hydrolyses phospholipids, and the resulting diacylglycerols
activate PKC [89,124]. PKC contains a redox-sensitive zinc-
binding site, and it is thought that through this site, the
cellular redox state regulates the activity of PKC [89]. The
link between zinc and cellular redox state is well established
[6]. PKC plays an important role in proteoglycan synthesis.
Proteoglycans are components of the extracellular matrix.
Their composition has been shown to be critical for lipid
retention, and hence, atherosclerosis [125]. Thus, modulating
PKC activity by Zn2+ will in turn regulate various vasoactive
factors that ultimately impact on the development of
atherosclerosis. Another group of zinc-dependent enzymes
critically involved in the extracellular matrix are the matrix
metalloproteinases. They are implicated in the response to
inflammation [126], and regulate the bioavailability and
activity of cytokines, chemokines, and growth factors. They
degrade the extracellular matrix, cell surface components as
well as intracellular proteins, and are therefore particularly
important for vascular and cardiac tissue remodelling, both
in normal conditions but also, e.g., during the development
of atherosclerosis [127] and the adverse structural
remodelling of the myocardium [128]. In atherosclerosis,
they may either stabilise or promote rupture of plaques, and
hence contribute to acute myocardial infarction [129]. Since
they require a zinc cofactor, their activity may be modulated
by zinc dyshomeostasis, although no detailed studies on this
hypothesis are available.
In addition, a lack of zinc is associated with apoptosis in
many cell types [130]. Endothelial cell injury and apoptosis
is a defining event in atherosclerosis [131], and it is thought
that oxidative stress resulting from lipid peroxidation and the
action of inflammatory cytokines is a major contributor to
these processes [11]. Zinc has both anti-inflammatory and
anti-oxidant effects [132], and it has been suggested that
Zn2+ performs a crucial role in maintaining the integrity of
endothelial cells [121]. Thus it is possible that chronically
lower plasma levels contribute to endothelial cell apoptosis.
In contrast, long-term zinc deprivation has also been shown
to accelerate rat VSMC proliferation via down-regulation of
the JNK1/2 pathway [133]. Accelerated VSMC proliferation
is a contributing factor in development of atherosclerosis
through thickening of the vascular wall [134].
Finally, one may also consider the effects of increased
free extracellular Zn2+. Although the anti-inflammatory
function of dietary zinc has been mentioned, the direct action
of Zn2+ on vascular endothelial cells induces inflammation
[135]. Induction of senescence by Zn2+ of VSMCs has also
been reported, and it is thought that this is mediated through
angiotensin [136]. More drastically, cell survival of primary
cultures of cardiomyocytes was negligible at only 0.6 µM
free Zn2+ [5].
5. FFA-loading of albumin as the molecular basis of
ischemia-modified albumin
Ischemia-modified albumin (IMA) is a biochemical
marker of myocardial ischemia (MI) for the detection and the
early diagnosis of acute coronary syndromes [137]. IMA can
be measured using the albumin-cobalt-binding (ACB) assay,
which was first established by Bar-Or et al. [138]. The ACB
assay has a high negative prognostic value, which is useful
in rapidly excluding ischemia as a cause of chest pain
changes in
cell
metabolism
increased VSMC
proliferation
pro-inflammatory
effects
oxidising
effects
atherosclerosis
elevated FFA levels
altered plasma
zinc speciation
altered cellular
Zn2+ uptake
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[65,139]. Despite this, the specificity of the test is low, with
increased IMA values also characteristic of various other
conditions including fatty liver, cancer, infections, renal
disease, preeclampsia, diabetes, stroke, and even sustained
exercise [140-145].
The basic principle of this test is such that following an
ischemic event, serum albumin is somehow chemically
modified such that its ability to bind Co2+ is compromised.
As a quantitative analytical method, the ACB test is
performed by the addition of CoCl2 to a patient plasma
sample, followed by the addition of dithiothreitol (DTT) to
complex the portion of Co2+ that has remained unbound to
serum albumin, and finally detection of a brown color
corresponding to formation of the Co-DTT complex [138].
The molecular basis for IMA and what it exactly is has
remained controversial. For some time it was incorrectly
assumed that the primary Co2+ binding site on albumin is at
the N-terminus and that ischemia leads to the cleavage of the
first two residues or some other oxidative modification such
that this metal binding site is effectively removed [64,146].
However, several efforts to prove a correlation between N-
terminal modification and positive ACB assay have failed
repeatedly [139,146,147]. Moreover, several in-vitro metal
binding studies since 2007 concluded that the N-terminal
ATCUN site is not the primary Co2+-binding site
[38,148,149].
Based on our identification of the location of MBS and
its allosteric regulation by fatty acids [33], Mothes and Faller
hypothesised in 2007 that the reduced Co2+ binding of IMA
may be related to fatty-acid inhibition of Co2+ binding to the
MBS [148]. Soon after, based on the observation that plasma
concentrations of FFAs rise during MI [150,151], a
relationship between FFAs and the reversible generation of
IMA was suggested [144], and Bhagavan et al. found a
"plausible but not causative relationship" between IMA
levels and FFA levels in the sera of patients with acute
myocardial infarction relative to controls, whereby an
increase in FFA levels resulted in a lower Co2+-binding
capacity, and hence an increase in IMA [60]. This explains
why positive ACB tests are also found in a plethora disorders
unrelated to MI, but which are associated with increased
plasma concentrations of FFAs [141,142,144,145].
Crucially, plasma FFAs are predominantly bound to
albumin in the circulation [152]. Based on our previous work
where we demonstrated interactive binding of FFAs and Zn2+
at the MBS [33,37], we examined the effects of FFAs on
Co2+ binding to albumin in vitro [149]. The results of this
study revealed that physiologically relevant concentrations
of the long chain FFA myristate were sufficient to reduce the
Co2+-binding affinity and capacity of bovine serum albumin
[149], in a manner broadly similar to that of Zn2+ [37].
Myristate binding to BSA was shown to inhibit metal
binding to both sites A (MBS) and B [37,149] (with the latter
being the primary Co2+ binding site [38]), resulting in a
decrease in total Co2+-binding site availability and a
corresponding increase in Co-DTT complex formation in the
ACB assay [149] (Figures 2e and 2f). The results of this
work, taken together with the already established link
between elevated plasma FFA levels and MI
[60,144,150,151], strongly suggest that IMA corresponds to
albumin with increased levels of bound FFAs and not N-
terminally modified albumin. These observations have
important implications for the detection of MI as they
suggest that “IMA” is strictly speaking neither a marker for
ischemia nor oxidative stress, but a proxy measurement of
plasma FFA levels.
Even though hypotheses based on permanent covalent
modifications are incompatible with the rapid clearance of
IMA within hours of the ischemic event - serum albumin has
a circulating half-life of 19 days! - and even though a 2012
study by Oh et al. categorically stated an "Insignificant role
of the N-terminal cobalt-binding site of albumin in the
assessment of acute coronary syndrome" - and even though
our own 2012 study had offered experimental evidence
supporting a coherent molecular mechanism that is
compatible with all clinical observations [149], many
researchers working in this area appear ignorant to this
collective evidence, with a host of recent publications
perpetuating the myth of N-terminal modification of albumin
being the basis for the assay [153-155]. Very recently Eom
et al., acknowledging that the N-terminus is not the primary
Co2+ binding site but still convinced that the N-terminus of
IMA is modified, even attempted to improve the ACB assay
through use of Cu2+ (rather than Co2+) [153], which has been
known for many years to bind strongly to albumin at the N-
terminus [20,22,38,39]. This new test was employed with
success, as was a previous attempt by others to use binding
of Ni2+ (the first equivalent of which also binds at the N-
terminus) as the basis of the assay [156]. In each case the
metal ion (either Cu2+ or Ni2+) bound, like Co2+, less
effectively to IMA than control albumin [153,156].
However, the concept of Cu2+ and Ni2+-binding to albumin
also being influenced by FFA-loading is not surprising as
113Cd-NMR and other spectroscopic studies previously
revealed the multi-metal site to be a strong secondary
binding site also for these metal ions following saturation of
the N-terminal site [20,39,40]. Therefore, as long as the
metal ion is added in excess over albumin, MBS will act as a
sensor for plasma FFA for all three M2+ mentioned. Indeed,
in the original ACB assay, 140 µM Co2+ and 90-100 µM
albumin are present [138]. In the nickel-based test, there was
a 3-fold excess of Ni over albumin [156], whereas we were
unable to establish the Cu:albumin ratio in the copper-based
test. We also note that site B, the primary Co2+ binding site,
is also FFA-responsive in BSA [37,149]; whether this is also
the case for HSA has not yet been established conclusively.
These observations are not meant to bring these
important diagnostic tests into disrepute; our main
motivation for this discussion is the desire that the molecular
basis for the test be well and truly understood. IMA can be
detected within minutes of an ischemic event, and remains
the only marker for the early detection of MI. We strongly
believe that metal-based tests detecting IMA are valuable
and should have their place in modern clinical diagnostics -
not only in MI, but other diseases related to elevated plasma
FFA. Indeed, a recent study has established that IMA is a
better prognostic marker than other biomarkers for peripheral
arterial occlusive disease [157].
CONCLUSIONS
CVD represents colossal challenges due to its huge
health burden on society. The importance of metals as
dietary factors and essential inorganic micronutrients capable
of modifying CVD has come to prominence only recently;
hence, guidelines from the national heart associations at
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present are mostly silent on the relation between CVD and
metal ions [89]. When the levels of circulatory trace metals
in blood become depleted, nutrient metals absorbed from the
diet are actively transported into blood and from there to
cells as needed. However, abnormalities in the ratios and
levels of trace metals will likely develop when this system
fails. Although albumin chemistry is of undoubted
importance in controlling the circulatory exchange of such
metals (and other ligands), many features of its chemistry are
yet to be fully understood. Here we have attempted to
illustrate this by examining the interplay between the MBS
and FFA binding to albumin. It is apparent that the
interactive binding of Zn2+ (and other metals that bind at this
site) and long-chain fatty acids has potential physiological
and clinical consequences. This is highlighted in the
discovery that IMA represents FFA-loaded albumin and that
the ACB assay is a proxy measurement of the FFA content
of albumin. However despite this, further work is necessary
to fully understand the physiological and pathological
importance of elevated FFA levels and their impact on
circulatory metal ion speciation. We envision that the work
highlighted here will motivate others to examine causes and
potential downstream effects of altered plasma metal ion
speciation. It is hoped that such studies will enable us to
better understand the molecular relationships that exist
between the transport of metabolites and metal ions in
plasma and their relevance to physiological and pathological
processes.
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